| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA751: Dupilumab for treating severe asthma |
|
Medicine details |
|
| Medicine name | dupilumab (Dupixent®) |
| Formulation | 200 mg and 300 mg subcutaneous injection |
| Reference number | 2456 |
| Indication | Add-on maintenance treatment in adults and adolescents aged 12 years and older for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO, who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment |
| Company | Sanofi |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/05/2019 |
| NICE guidance | |